

Listing of the Claims:

The following listing of claims will replace all prior versions and listings of claims in the application.

1.-46. (Canceled)

45. (Currently Amended) A pharmaceutical composition comprising an isolated hyperimmune serum-reactive antigen comprising an amino acid sequence of SEQ ID NO: 364 or an immunogenic fragment of SEQ ID NO: 364 comprising one or more of amino acid sequences 414-420, 427-437, 455-475, 494-510, 386-458, or 458-624 of SEQ ID NO:364 or fragment of claim 38.

46. (Previously Presented) The pharmaceutical composition of claim 45, wherein the hyperimmune serum-reactive antigen or fragment is directed against *S. agalactiae*.

47. (Previously Presented) The pharmaceutical composition of claim 45, further defined as comprising at least two different hyperimmune serum-reactive antigens and/or fragments.

48. (Previously Presented) The pharmaceutical composition of claim 47, wherein the at least two different hyperimmune serum-reactive antigens and/or fragments are both directed against *S. agalactiae*.

49. (Previously Presented) The pharmaceutical composition of claim 45, further comprising an immunostimulatory substance.

50. (Previously Presented) The pharmaceutical composition of claim 49, wherein the immunostimulatory substance is a polycationic polymer, an immunostimulatory deoxynucleotide (ODN), a peptide containing at least two LysLeuLys motifs, a neuroactive compound, alum, or a Freund's complete or incomplete adjuvant.

51. (Withdrawn) The pharmaceutical composition of claim 50, wherein the polycationic polymer is a polycationic peptide.

52. (Withdrawn) The pharmaceutical composition of claim 50, wherein the neuroactive compound is human growth hormone.

53. (Previously Presented) The pharmaceutical composition of claim 45, further defined as a vaccine.

54. (Previously Presented) The pharmaceutical composition of claim 53, further defined as a vaccine for treatment and/or prevention of *S. agalactiae* infection.

55. (Withdrawn) A method of vaccinating a subject comprising:
obtaining a pharmaceutical composition of claim 45; and
administering the pharmaceutical composition to a subject;
wherein the subject is vaccinated.

56. (Withdrawn) The method of claim 55, wherein the subject is a human.

57. (Withdrawn) The method of claim 55, further defined as a method of treating and/or preventing *S. agalactiae* infection in the subject.

58. (Withdrawn) The method of claim 55, wherein the hyperimmune serum-reactive antigen or fragment is directed against *S. agalactiae*.

59. (Withdrawn) The method of claim 55, wherein the pharmaceutical composition comprises at least two different hyperimmune serum-reactive antigens or fragments thereof.

60. (Withdrawn) The method of claim 59, wherein the at least two different hyperimmune serum-reactive antigens or fragments thereof are both directed against *S. agalactiae*.

61. (New) A pharmaceutical composition comprising:

- (a) an isolated hyperimmune serum-reactive antigen comprising an amino acid sequence of SEQ ID NO: 364 or an immunogenic fragment of SEQ ID NO: 364 comprising one or more of amino acid sequences 414-420, 427-437, 455-475, 494-510, 386-458, or 458-624 of SEQ ID NO:364; and
- (b) an immunostimulatory substance.